AC Immune SA

Equities

ACIU

CH0329023102

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 01:18:48 2024-05-23 pm EDT			5-day change	1st Jan Change
3.725 ^USD	+7.97%		+6.89%	-27.10%

May. 13	Sector Update: Health Care Stocks Mixed Late Afternoon	MT
May. 13	Sector Update: Health Care	MT

AC Immunity Shares Soar on Exclusive License Deal with Takeda

May 13, 2024 at 07:26 am EDT

By Dean Seal

Shares of AC Immunity surged after the company signed announced an agreement with Takeda Pharmaceutical for an exclusive option to license its active immunotherapy for Alzheimer's disease.

The stock was up 64% at $3.80 in premarket trading. Shares had fallen by more than 50% year-to-date when the market closed Friday.

The biopharmaceutical company said Monday morning that Takeda will receive an exclusive option to license global rights to ACT-24.060, AC Immune's active immunotherapy designed to delay or slow Alzheimer's disease progression.

AC Immune is set to receive an upfront payment of $100 million upon closing and be eligible for additional milestone payments of up to $2.1 billion.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

05-13-24 0726ET

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	TAKEDA PHARMACEUTICAL COMPANY LIMITED	4,134 JPY	+0.78%	-0.60%	41.12B
	AC IMMUNE SA	3.66 USD	+6.09%	+6.46%	324M

Latest news about AC Immune SA

Sector Update: Health Care Stocks Mixed Late Afternoon	May. 13	MT
Sector Update: Health Care	May. 13	MT
Top Midday Gainers	May. 13	MT
AC Immune Enters Licensing Deal for Alzheimer's Disease Drug Candidate	May. 13	MT
Wall Street Set to Open Higher Monday as Investors Look Toward Key Inflation Figures	May. 13	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Ahead of Key Inflation Reports	May. 13	MT
Investors Eye Key Inflation Data in Days Ahead as US Futures Trend Modestly Higher Monday	May. 13	MT
Top Premarket Gainers	May. 13	MT
Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate	May. 13	MT
AC Immunity Shares Soar on Exclusive License Deal with Takeda	May. 13	DJ
AC Immune SA Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
AC Immune Files $350 Million Mixed Shelf	Mar. 15	MT
AC Immune SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Certain Common Shares of AC Immune SA are subject to a Lock-Up Agreement Ending on 14-FEB-2024.	Feb. 13	CI
AC Immune to Regain Global Rights of Crenezumab, Semorinema	Jan. 22	MT
Roche terminates licensing agreement with AC Immune	Jan. 22	CF
AC Immune SA Announces Termination of the Research Collaboration and License Agreement with Genentech, Inc	Jan. 22	CI
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson's Diseases	Jan. 03	CI
AC Immune SA(NasdaqGM:ACIU) added to NASDAQ Biotechnology Index	Dec. 18	CI
Sector Update: Health Care Stocks Retreating Late Afternoon	Dec. 15	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	Dec. 15	MT
AC Immune SA Announces its Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial	Dec. 15	CI
AC Immune to Launch Mid-Stage Trial of Alzheimer's Disease Therapy; Prices $50.1 Million Common Stock Offering; Shares Rise	Dec. 15	MT
AC Immune Officially Names Christopher Roberts as CFO	Dec. 01	MT
AC Immune SA Announces the Promotion of Christopher Roberts from Interim Chief Financial Officer to Chief Financial Officer, Effective January 1, 2024	Dec. 01	CI

Chart AC Immune SA

Duration

Period

More charts

Company Profile

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimerâs disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for AC Immune SA

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.153 CHF

Average target price

9.984 CHF

Spread / Average Target

+216.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AC IMMUNE SA	-27.40%	324M
MODERNA, INC.	+64.74%	62.59B
IQVIA HOLDINGS INC.	-1.05%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.93%	27.9B
ICON PUBLIC LIMITED COMPANY	+13.41%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.47%	19.09B
BIO-TECHNE CORPORATION	+5.07%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.72%	12.26B
MEDPACE HOLDINGS, INC.	+28.81%	12.05B

Other Biotechnology & Medical Research